## Mucormycosis: Clinical Features and Pathobiology ### Clinical Presentation **Key Point:** The patient's presentation — black necrotic palatal tissue, rhinosinusitis, and diabetes mellitus — is pathognomonic for **rhinocerebral mucormycosis**, a medical emergency. **High-Yield:** Broad, non-septate hyphae with right-angle branching = **Mucorales order** (Rhizopus, Mucor, Rhizomucor, Lichtheimia). ### Pathophysiology | Feature | Mechanism | Clinical Consequence | |---|---|---| | **Obligate aerobe** | Requires O₂; prefers well-oxygenated tissues | Lung and sinus involvement common | | **Angioinvasion** | Hyphae invade blood vessel walls | Thrombosis → tissue necrosis → black eschar | | **Rapid progression** | Exponential hyphal growth | Hours to days from infection to dissemination | | **Immunosuppression** | Neutropenia, diabetes, transplant | Risk factors: DKA, hematologic malignancy, iron overload | **Clinical Pearl:** The black, necrotic appearance of mucormycosis is due to vascular invasion causing thrombosis and infarction — not pigment production. This distinguishes it from aspergillosis (which causes hemorrhage but not characteristic necrosis). ### Iron and Mucormycosis: The Deferoxamine Paradox **Warning:** Deferoxamine is CONTRAINDICATED in mucormycosis, not inhibitory. **Key Point:** Mucorales have high-affinity iron uptake systems. Deferoxamine, an iron chelator, **increases bioavailable iron** in a form that Mucorales can utilize, thereby **promoting fungal growth** — this is a well-documented risk factor for mucormycosis in dialysis patients and those with iron overload. **High-Yield:** Patients on deferoxamine (e.g., chronic kidney disease with transfusion-dependent anemia) have increased mucormycosis risk. If mucormycosis develops, deferoxamine must be discontinued immediately. ### Epidemiology **Key Point:** Rhizopus species account for 50–90% of mucormycosis cases globally, followed by Mucor and Rhizomucor. ### Management **High-Yield:** The "gold standard" is **aggressive surgical debridement + high-dose liposomal amphotericin B (AmB-L)**: 1. **Immediate surgical debridement** of all necrotic tissue (may require multiple procedures) 2. **IV amphotericin B-liposomal** 10 mg/kg/day (conventional AmB is less effective) 3. **Control of underlying diabetes** (insulin, metabolic optimization) 4. **Imaging surveillance** (MRI/CT) to assess extent and response **Clinical Pearl:** Mortality remains 20–50% even with optimal treatment; delay in diagnosis and surgery significantly worsens prognosis. [cite:Robbins 10e Ch 8; Harrison 21e Ch 215]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.